Relationship between tamoxifen use and high risk endometrial cancer histologic types

Gynecologic Oncology

Volumn 112, Issue 1, 2009, Pages 150-154

  Bland, Amy E ^a,b   Calingaert, Brian ^b   Secord, Angeles Alvarez ^a,b   Lee, Paula S ^a,b   Valea, Fidel A ^a,b   Berchuck, Andrew ^a,b   Soper, John T ^c,d   Havrilesky, Laura ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Breast cancer; Endometrial cancer; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DRUG USE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PAPILLARY CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; YOUNG ADULT;

EID: 57649108536     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.08.035     Document Type: Article

References (27)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N. Engl. J. Med. 319 26 (1988) 1681-1692
2. Ryden S., Ferno M., Moller T., Aspegren K., Bergljung L., Killander D., et al. Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial. Acta. Oncol. 31 2 (1992) 271-274
3. Rutqvist L.E., Johansson H., Signomklao T., Johansson U., Fornander T., and Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J. Natl. Cancer Inst. 87 9 (1995) 645-651
4. Andersson M., Storm H.H., and Mouridsen H.T. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J. Natl. Cancer Inst. 83 14 (1991) 1013-1017
5. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., and Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86 7 (1994) 527-537
6. Curtis R.E., Boice Jr. J.D., Shriner D.A., Hankey B.F., and Fraumeni Jr. J.F. Second cancers after adjuvant tamoxifen therapy for breast cancer. J. Natl. Cancer Inst. 88 12 (1996) 832-834
7. Barakat R.R., Wong G., Curtin J.P., Vlamis V., and Hoskins W.J. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol. Oncol. 55 2 (1994) 164-168
8. Barakat R.R. Tamoxifen and the endometrium. Cancer Treat. Res. 94 (1998) 195-207
9. Jordan V.C., and Assikis V.J. Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin. Cancer Res. 1 5 (1995) 467-472
10. Matsuyama Y., Tominaga T., Nomura Y., Koyama H., Kimura M., Sano M., et al. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan. Ann. Oncol. 11 12 (2000) 1537-1543
11. Slomovitz B.M., Sun C.C., Ramirez P.T., Bodurka D.C., Diaz P., and Lu K.H. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?. Obstet. Gynecol. 104 2 (2004) 255-260
12. Bergman L., Beelen M.L., Gallee M.P., Hollema H., Benraadt J., and van Leeuwen F.E. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356 9233 (2000) 881-887
13. Magriples U., Naftolin F., Schwartz P.E., and Carcangiu M.L. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Clin. Oncol. 11 3 (1993) 485-490
14. Mignotte H., Lasset C., Bonadona V., Lesur A., Luporsi E., Rodier J.F., et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Int. J. Cancer 76 3 (1998) 325-330
15. Rieck G.C., Freites O.N., and Williams S. Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer. J. Obstet. Gynaecol. 25 1 (2005) 39-41
16. Lewis-Wambi J.S., and Jordan V.C. Treatment of postmenopausal breast cancer with selective estrogen receptor modulators (SERMs). Breast Dis. 24 (2005) 93-105
17. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 9472 (2005) 1687-1717
18. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 9114 (1998) 1451-1467
19. Hoogendoorn W.E., Hollema H., van Boven H.H., Bergman E., de Leeuw-Mantel G., Platteel I., et al. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Res. Treat. (2007)
20. Swerdlow A.J., and Jones M.E. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J. Natl. Cancer Inst. 97 5 (2005) 375-384
21. Hornreich G., Beller U., Lavie O., Renbaum P., Cohen Y., and Levy-Lahad E. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol. Oncol. 75 2 (1999) 300-304
22. Goshen R., Chu W., Elit L., Pal T., Hakimi J., Ackerman I., et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?. Gynecol. Oncol. 79 3 (2000) 477-481
23. Geisler J.P., Sorosky J.I., Duong H.L., Buekers T.E., Geisler M.J., Sood A.K., et al. Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma. Gynecol. Oncol. 83 3 (2001) 501-503
24. Lavie O., Hornreich G., Ben Arie A., Renbaum P., Levy-Lahad E., and Beller U. BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet. Gynecol. 96 1 (2000) 28-32
25. Bandera C.A., Muto M.G., Schorge J.O., Berkowitz R.S., Rubin S.C., and Mok S.C. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet. Gynecol. 92 4 Pt 1 (1998) 596-600
26. Gehrig P.A., Bae-Jump V.L., Boggess J.F., Groben P.A., Fowler Jr. W.C., and Van Le L. Association between uterine serous carcinoma and breast cancer. Gynecol. Oncol. 94 1 (2004) 208-211
27. Sherman M.E., Sturgeon S., Brinton L.A., Potischman N., Kurman R.J., Berman M.L., et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod. Pathol. 10 10 (1997) 963-968